Global Blood Therapeutics, Inc.
Global Blood Therapeutics, Inc. (GBT) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
gbt · stock forecast · 29 analysts (3M) · FMP · updated Dec 4, 2023
Analyst Rating & Consensus
Based on 29 Wall Street analysts in the past 3 months
Buy
29 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$110
Consensus
$60.38
-11.8% upside
Low
$36.00
Median: $59 · Last Close: $68.49
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Consensus Target
$60.38
-11.8% upside
High Target
$110
60.6%
Low Target
$36
-47.4%
Current Price
$68.49
as of today
Based on analyst price targets, the GBT stock price prediction for the next 12 months ranges from $36 to $110. The consensus GBT price forecast of $60.38 implies -11.8% upside from the current price of $68.49.
Short-Term Price Prediction
RangingAlgorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-10 | $68.60 | ↑ 0.16% |
1-day model range: $68.57–$68.63. Peak: $68.63 (+0.16%).
Long-Term Stock Price Prediction
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
NEUTRAL
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · GBT · Jun 9, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2022-08-19 | Cantor Fitzgerald | Downgrade ↓ | Overweight→Neutral |
| 2022-08-09 | RBC Capital | Downgrade ↓ | Outperform→Perform |
| 2022-08-09 | SVB Leerink | Downgrade ↓ | Outperform→Perform |
| 2022-08-09 | Cantor Fitzgerald | Downgrade ↓ | Overweight→Neutral |
| 2022-08-09 | Wells Fargo | Downgrade ↓ | Overweight→Equal Weight |
| 2022-08-08 | Jefferies | Downgrade ↓ | Buy→Hold |
| 2022-08-08 | Canaccord Genuity | Upgrade ↑ | Hold→Buy |
| 2022-08-08 | Stifel | Downgrade ↓ | Buy→Hold |
| 2022-08-08 | Wedbush | Downgrade ↓ | Outperform→Neutral |
| 2022-06-28 | JP Morgan | Maintains | Neutral→Neutral |
Wall Street analysts have recently issued updated ratings on Global Blood Therapeutics, Inc. (GBT) stock. Of the recent 79 rating actions, 4 were upgrades and 12 were downgrades. 29 analysts currently cover GBT.
Analyst Recommendation Trends
GBT analyst recommendation trends show stable buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 1 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
—
Revenue Next Year
—
EPS This Year
—
EPS Next Year
—
EPS ForecastReported vs Estimated
Analysts forecast GBT EPS of $— for the current fiscal year, based on estimates from 0 analysts. The GBT revenue forecast is — for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The GBT stock forecast is supported by two independent data sources: analyst consensus ratings from 29 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus GBT price target is $60.38 (-11.8% upside), with an analyst consensus of Buy.
The GBT short-term stock prediction for tomorrow is $68.60 (+0.16%).
Global Blood Therapeutics, Inc. trades on NASDAQ under the ticker GBT. The GBT stock outlook for 2027 is broadly positive, supported by a Buy consensus among 62% of covering analysts.
Frequently asked questions
GBT forecast · 8 questionsAccording to 29 Wall Street analysts, the average 12-month GBT price target is $60.38, with a high forecast of $110.00 and a low of $36.00. The median price target is shown in the chart above when available. This implies -11.8% potential upside from the current price of $68.49.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.